A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults

PURPOSE: In this dose-finding Phase II study (NCT00621322), we evaluated the safety and immunogenicity of different formulations of the candidate tuberculosis vaccine containing the M72 antigen (10/20/40 μg doses) and the liposome-based AS01 Adjuvant System. We aimed to select the lowest-dose combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Montoya, Jaime, Solon, Juan Antonio, Cunanan, Soledad Rosanna C., Acosta, Luz, Bollaerts, Anne, Moris, Philippe, Janssens, Michel, Jongert, Erik, Demoitié, Marie-Ange, Mettens, Pascal, Gatchalian, Salvacion, Vinals, Carlota, Cohen, Joe, Ofori-Anyinam, Opokua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825318/
https://www.ncbi.nlm.nih.gov/pubmed/24142232
http://dx.doi.org/10.1007/s10875-013-9949-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825318/
https://www.ncbi.nlm.nih.gov/pubmed/24142232
http://dx.doi.org/10.1007/s10875-013-9949-3

Ejemplares similares